Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in hurler syndrome

American Journal of Pediatric Hematology/Oncology

Volumn 22, Issue 5, 2000, Pages 433-436

  Kapelushnik, J ^a,c   Mandel, H ^b   Varadi, G ^a   Nagler, A ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Fludarabine; Haploidentical peripheral blood stem cell transplant; Hurler syndrome; T cell depletion

Indexed keywords

DRUG DERIVATIVE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; VIDARABINE;

ADOLESCENT; ALLOTRANSPLANTATION; ANIMAL; ARTICLE; CASE REPORT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HURLER SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; MALE; RABBIT; RAT;

ADOLESCENT; ANIMALS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MUCOPOLYSACCHARIDOSIS I; RABBITS; RATS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 0034265810     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200009000-00009     Document Type: Article

References (35)

1. Neufeld E, Muenzer J. The mucopolysaccharides. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol. 2. New York: McGraw-Hill, 1995: 2465-94.
2. Hobbs JR, Hugh-Jones K, Barrett AJ, et al. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone marrow transplantation. Lancet 1981; 2: 709-12.
3. Hugh-Jones K. Psychomotor development of children with mucopolysaccharidosis type I-H following bone marrow transplantation. Birth Defects 1986; 22: 25-9.
4. Krivit W, Whitley CB, Chang PN, et al. Lysosomal storage diseases treated by bone marrow transplantation. In: Gale RP, Champlin RE, eds. Bone Marrow Transplantation. New York: Alan R. Liss, 1988: 367-89.
5. Hugh-Jones K, Hobbs JR, di Vello A, et al. Long-term follow-up of children with Hurler’s disease treated with bone marrow transplantation. In: Hobbs JR, ed. Correction of Certain Genetic Diseases by Transplantation. London: Cogent, 1989: 103-7.
6. Whitley CB, Belani KG, Chang PN, et al. Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 1993; 46: 209-18.
7. Peters C, Shapiro EG, Anderson J, et al. Hurler Syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. Blood 1998; 91: 2601-8.
8. Marks DI, Cullis JO, Ward KN, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. Ann Intern Med 1993; 119: 207-14.
9. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593-602.
10. Gale RP, Horowitz MM. Predicting results of alternative donor transplants for thalassemia using a chronic myelogenous leukemia model. Bone Marrow Transplant 1993; 12: 82-3.
11. Kapelushnik J, Varadi G, Nagler A. Matched unrelated human umbilical cord blood transplantation for X-linked adrenoleukodystrophy. J Pediatr Hematol Oncol 1998; 20: 257-9.
12. Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996; 87: 4894-902.
13. Winiarski J, Ringden O, Remberger M, et al. Bone marrow transplantation in children using unrelated donors at Huddinge Hospital. Acta Paediat 1996; 85: 327-35.
14. Locatelli F, Pession A, Comoli P, et al. Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukemia. Br J Haematol 1996; 92: 49-54.
15. Grovas A, Feig SA, O’Rourke S, et al. Unrelated donor bone marrow transplants in children. Cell Transplant 1994; 3: 413-20.
16. Aversa F. Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical " three-loci” incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-55.
17. Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16: 437-40.
18. Aversa F. Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-93.
19. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: A mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617-25.
20. Parker W, Cheng Y-C. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol Pharmacol 1987; 31;146-51.
21. Yang S-W, Huang P, Plunkett W, et al. Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992; 267: 2345-9.
22. Huang P, Plunkett W. Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism. Mol Pharmacol 1991; 39: 449-55.
23. 1--deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-50.
24. Slavin S, Nagler A, Naparstek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-63.
25. Naparstek E, Hardan Y, Ben-Shahar M, et al. Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992; 80: 1673-8.
26. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273-5.
27. Hobbs JR. Bone marrow transplantation for inborn errors. Lancet 1981; 2: 735-9.
28. Beutler E. Bone marrow transplantation beyond treatment of aplasia and neoplasia. West J Med 1994; 160: 129-32.
29. Bushhouse S, Ramsay NKC, Pescovitz OH, et al. Growth in children following irradiation for bone marrow transplantation. Am J Pediatr Hematol Oncol 1989; 11: 134-40.
30. Kapelushnik J, Or R, Slavin S, Nagler A. Case report: A fludarabine-based protocol for bone marrow transplantation in Fanconi’s anemia. Bone Marrow Transplant 1997; 20: 1109-10.
31. Aker M, Varadi G, Slavin S, Nagler A. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi’s anemia. J Pediatr Hematol Oncol 1999; 21: 237-9.
32. Nagler A, Ackerstein A, Kapelushnik J, et al. Donor lymphocyte infusion post-nonmyeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 1999, 24: 339-42.
33. Nagler A, Or R, Naparstek E, et al. Matched unrelated bone marrow transplantation (BMT) using a non-myeloablative conditioning regimen. Blood 1998;92(Suppl)298a.
34. Lenarsky C, Parkman R. Bone marrow transplantation for the treatment of immune deficiency states. Bone Marrow Transplant 1990; 6: 361-9.
35. Naparstek E, Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br J Haematol 1995; 89: 506-15.